CA2605878A1 - Attenuated human parainfluenza virus, methods and uses thereof - Google Patents

Attenuated human parainfluenza virus, methods and uses thereof Download PDF

Info

Publication number
CA2605878A1
CA2605878A1 CA002605878A CA2605878A CA2605878A1 CA 2605878 A1 CA2605878 A1 CA 2605878A1 CA 002605878 A CA002605878 A CA 002605878A CA 2605878 A CA2605878 A CA 2605878A CA 2605878 A1 CA2605878 A1 CA 2605878A1
Authority
CA
Canada
Prior art keywords
protein
recombinant
paramyxovirus
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002605878A
Other languages
English (en)
French (fr)
Inventor
Mario H. Skiadopoulos
Brian R. Murphy
Peter L. Collins
Sheila Nolan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2605878A1 publication Critical patent/CA2605878A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002605878A 2005-01-12 2006-01-10 Attenuated human parainfluenza virus, methods and uses thereof Abandoned CA2605878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64331005P 2005-01-12 2005-01-12
US60/643,310 2005-01-12
PCT/US2006/000666 WO2007120120A2 (en) 2005-01-12 2006-01-10 Attenuated human parainfluenza virus, methods and uses thereof

Publications (1)

Publication Number Publication Date
CA2605878A1 true CA2605878A1 (en) 2007-10-25

Family

ID=38429996

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002605878A Abandoned CA2605878A1 (en) 2005-01-12 2006-01-10 Attenuated human parainfluenza virus, methods and uses thereof

Country Status (6)

Country Link
US (1) US9034343B2 (enExample)
EP (1) EP1877548B1 (enExample)
JP (1) JP2008537683A (enExample)
AU (1) AU2006332044A1 (enExample)
CA (1) CA2605878A1 (enExample)
WO (1) WO2007120120A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0909547A2 (pt) * 2008-05-26 2019-03-06 Cadila Healthcare Ltd. vacina combinada de sarampo - hpv, vetor e hospedero
JP5807917B2 (ja) * 2011-02-08 2015-11-10 国立大学法人三重大学 遺伝子導入用ウイルスベクターの製造方法
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
EP3247388B1 (en) 2015-01-20 2025-09-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
EP3601617B3 (en) 2017-03-24 2024-03-20 Gen-Probe Incorporated Compositions and methods for detecting or quantifying parainfluenza virus
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
CN113999292B (zh) * 2021-10-27 2023-05-26 中国农业大学 靶向呼吸道病毒属病毒的多肽抑制剂
CN121379992A (zh) * 2025-10-27 2026-01-23 榆林学院 一种牛副流感病毒3型v蛋白缺失毒株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69419913T2 (de) 1993-05-14 2000-02-17 Orbital Engine Co. (Australia) Pty. Ltd., Balcatta Induktionssystem einer internen brennkraftmaschine
US20030082209A1 (en) * 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US7820181B2 (en) * 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens

Also Published As

Publication number Publication date
WO2007120120A3 (en) 2008-06-26
AU2006332044A8 (en) 2008-08-07
WO2007120120A2 (en) 2007-10-25
US9034343B2 (en) 2015-05-19
EP1877548A2 (en) 2008-01-16
EP1877548B1 (en) 2016-01-06
JP2008537683A (ja) 2008-09-25
AU2006332044A1 (en) 2007-08-16
US20130052718A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
US7919301B2 (en) Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from CDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP4813710B2 (ja) 非必須遺伝子の欠失あるいは除去により弱毒化された組換えパラインフルエンザウイルスワクチン
US20080279892A1 (en) Recombinant RSV Virus Expression Systems And Vaccines
AU2009202359A1 (en) Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2003504064A (ja) 弱毒ヒト−ウシキメラ−パラインフルエンザウイルス（ｐｉｖ）ワクチン
EP1480671B1 (en) Recombinant rsv virus expression systems and vaccines
US20120308602A1 (en) Recombinant RSV Virus Expression Systems And Vaccines
US9034343B2 (en) Attenuated human parainfluenza virus, methods and uses thereof
Nolan et al. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses
EP2152863B1 (en) Human parainfluenza viruses having separated p and c genes
US20060099226A1 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US20110189232A1 (en) RECOMBINANT HUMAN PARAINFLUENZA TYPE 1 VIRUSES (HPIV1s) CONTAINING MUTATIONS IN OR DELETION OF THE C PROTEIN ARE ATTENUATED IN AFRICAN GREEN MONKEYS AND IN CILIATED HUMAN AIRWAY EPITHELIAL CELLS AND ARE POTENTIAL VACCINE CANDIDATES FOR HPIV1
AU2005201040A1 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130110